Chinese pharmaceutical company Jacobio Pharma (HK:1167) announced on Thursday the presentation of its internally discovered pan-KRAS inhibitor JAB-23E73 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics.

The pre-clinical results demonstrated that JAB-23E73 is a highly potent pan-KRAS (ON/OFF) inhibitor with strong selectivity that spares HRAS and NRAS inhibition. The compound exhibits superior anti-tumour activity across multiple cancer types harbouring different KRAS driver mutations or amplification, Jacobio said.

In KRAS-driven mouse tumour models, JAB-23E73 induced tumour regression without causing significant body weight loss, indicating good tolerability and a wide therapeutic window. The compound also showed a favourable pharmacokinetic profile for oral administration and exhibited plasma drug concentration-dependent intra-tumoural p-ERK inhibition.

Phase I clinical trials of JAB-23E73 are currently ongoing in both China and the United States for patients with advanced solid tumours harbouring KRAS gene alterations.

Jacobio's R&D centres are located in Beijing, Shanghai (China), and Boston (USA). Clinical trials are conducted at over 180 sites in China, more than 30 sites in the USA, and over 10 sites across several European countries.